Join the Kisqali group to help and get support from people like you.
Kisqali News
FDA approves Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant t...
FDA Expands Use of Breast Cancer Drug Kisqali
WEDNESDAY, Sept. 18, 2024 – Women with early stage breast cancer may now take Kisquali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded...
FDA Medwatch Alert: Drug Safety Communication: Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) - Rare but Severe Lung Inflammation
September 13, 2019 ISSUE: FDA is warning that Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib) used to treat some patients with advanced breast cancers may cause rare but ...
Kisqali (ribociclib) Approved for Additional Indications in HR+/HER2- Advanced Breast Cancer
Basel, July 18, 2018 - Novartis today announced a new approval for Kisqali (ribociclib) from the US Food and Drug Administration (FDA) for women with hormone-receptor positive, human epidermal growth...
FDA Approves Kisqali (ribociclib) for HR+/HER2- Metastatic Breast Cancer
Basel, March 13, 2017 - The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based...
Further information
Related condition support groups
Breast Cancer, Metastatic, Breast Cancer